Skip to main navigation Skip to search Skip to main content

A two year phase III randomized double blind paralled group placebo controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo in combination with SoC therapy inpatients with active lupus n

Upstate Medical University

Project: Research

Project Details

StatusActive
Effective start/end date03/1/21 → 12/1/26

Funding

  • Novartis Pharmaceuticals Corporation: $24,772.82